title: Evidence for pyronaridine as a highly effective partner drug for treatment of artemisinin-resistant malaria in a rodent model.
abstract: The increasing prevalence in Southeast Asia of Plasmodium falciparum infections with delayed parasite clearance rates, following treatment of malaria patients with the artemisinin derivative artesunate, highlights an urgent need to identify which of the currently available artemisinin-based combination therapies (ACTs) are most suitable to treat populations with emerging artemisinin resistance. Here, we demonstrate that the rodent Plasmodium berghei SANA strain has acquired artemisinin resistance following drug pressure, as defined by reduced parasite clearance and early recrudescence following daily exposure to high doses of artesunate or the active metabolite dihydroartemisinin. Using the SANA strain and the parental drug-sensitive N strain, we have interrogated the antimalarial activity of five ACTs, namely, artemether-lumefantrine, artesunate-amodiaquine, artesunate-mefloquine, dihydroartemisinin-piperaquine, and the newest combination artesunate-pyronaridine. By monitoring parasitemia and outcome for 30 days following initiation of treatment, we found that infections with artemisinin-resistant P. berghei SANA parasites can be successfully treated with artesunate-pyronaridine used at doses that are curative for the parental drug-sensitive N strain. No other partner drug combination was as effective in resolving SANA infections. Of the five partner drugs tested, pyronaridine was also the most effective at suppressing the recrudescence of SANA parasites. These data support the potential benefit of implementing ACTs with pyronaridine in regions affected by artemisinin-resistant malaria.
authors.affiliation: Department of Microbiology and Immunology, Columbia University Medical Center, New York, New York, USA.
authors.forename: Philipp P
authors.initials: PP
authors.lastname: Henrich
authors.forename: Connor
authors.initials: C
authors.lastname: O'Brien
authors.forename: Fabián E
authors.initials: FE
authors.lastname: Sáenz
authors.forename: Serge
authors.initials: S
authors.lastname: Cremers
authors.forename: Dennis E
authors.initials: DE
authors.lastname: Kyle
authors.forename: David A
authors.initials: DA
authors.lastname: Fidock
mesh_terms: D000655:Amodiaquine / Q000627:therapeutic use; D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D037621:Artemisinins / Q000627:therapeutic use*; D000077332:Artesunate; D004338:Drug Combinations; D004351:Drug Resistance; D005260:Female; D005434:Flow Cytometry; D016778:Malaria, Falciparum / Q000188:drug therapy*; D015767:Mefloquine / Q000627:therapeutic use; D051379:Mice; D009287:Naphthyridines / Q000627:therapeutic use
chemical_list: D000962:Antimalarials; D037621:Artemisinins; D004338:Drug Combinations; D009287:Naphthyridines; C515299:amodiaquine, artesunate drug combination; D000655:Amodiaquine; D000077332:Artesunate; C039060:artenimol; C031327:artemisinin; C027871:pyronaridine; D015767:Mefloquine